

FULBRIGHT & JAWORSKI L.L.P.
 A REGISTERED LIMITED LIABILITY PARTNERSHIP
 600 CONGRESS AVENUE, SUITE 2400
 AUSTIN, TEXAS 78701-3271
 WWW.FULBRIGHT.COM

RECEIVED
CENTRAL FAX CENTER

NOV 15 2005

FACSIMILE TRANSMISSION

DATE: November 15, 2005

MATTER NUMBER:

10511569

DFBP:008USC2

RECIPIENT:	FAX NO.:	PHONE NO.:
Commissioner for Patents U.S. Patent Office	571/273-8300	703/308-1202

FROM: Martha Robinson

USER ID: MR10031 **FLOOR:** 20

PHONE: (512) 536-5616

FAX: (512) 536-4598

RE: CUSTOMER NO. 32425, POWER OF ATTORNEY

NUMBER OF PAGES WITH COVER PAGE: 10 **Originals Will Not Follow**

Message:

Please enter in the following matter:

U.S. Patent Application No. 10/031,188, entitled "KERATINOCYTE CULTURE AND USES THEREOF", by Thomas Hunziker and Alain Limat

Thank you for your attention to this matter.

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

**IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
 MARTHA ROBINSON @ 512/536-5616 AS SOON AS POSSIBLE.**

NOV 15 2005

002

MODIFIED PTO/SB/196 (09-04)

STATEMENT UNDER 37 CFR 3.73(B)Applicant/Patent Owner: Thomas Hunziker and Alain LimatApplication No./Patent No. 10/031,188 Filed/Issue Date: May 13, 2002Entitled: **KERATINOCYTE CULTURE AND USES THEREOF**DFB Pharmaceuticals, Inc.

(Name of Assignee)

a Corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:


A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.**OR**B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Thomas Hunziker, Alain Limat To: Epitech SA
The document was recorded in the United States Patent and Trademark Office at Reel 012854, Frame 0291, or for which a copy thereof is attached.
2. From: Epitech SA To: Modex Therapeutiques SA (now known as Isotis SA)
The document was recorded in the United States Patent and Trademark Office at Reel 015312, Frame 0034, or for which a copy thereof is attached.
3. From: Modex Therapeutiques SA (now known as Isotis SA) To: Episource SA
The document was recorded in the United States Patent and Trademark Office at Reel 015409, Frame 0185, or for which a copy thereof is attached.

 Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.081

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

November 15, 2005

Date

Mark B. Wilson, Reg. No. 37,259(512) 474-5201

Printed or Typed Name

Telephone Number

AttorneyDFBP:008USC2Title

File Code

STATEMENT UNDER 37 CFR 3.73(b)

Page 2
DFBP:008USC2

3. From: Episource SA To: DFB Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

PTO/SB/80 (04-05)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

Practitioners associated with the Customer Number:

32425

OR

Practitioner(s) named below (If more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

The address associated with Customer Number:

32425

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Email		

Assignee Name and Address:

DFB Pharmaceuticals, Inc.
318 McCullough
San Antonio, TX 78216

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	7 Nov. 2005.
Name	Mark Mitchell	Telephone	210-476-8180
Title	General Counsel and Vice President Regulatory Compliance		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label No.:
Date of Deposit:

EV475167504US
February 16, 2005

Attorney Docket No.: 1781t-999

ASSIGNMENT

EpiSource SA, a corporation organized under the laws of Switzerland, having principal offices at 1 Rue de Sébillion, 1004 Lausanne, Switzerland ("the ASSIGNOR"), the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to DFB Pharmaceuticals, Inc., a corporation organized under the laws of Texas, having principal offices at 3909 Hulen Street, Fort Worth, Texas 76107, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE: (1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in the name of EpiSource SA at the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patents which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

EpiSource SA hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by EpiSource SA had this assignment, sale and transfer not been made.

EpiSource SA agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.


EpiSource SA further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

EpiSource SA hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.


Attorney Docket No.: 17811-999

EpiSource SA further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

Attorney Docket No.: 17811-999

For EpiSource SA:Date: December 15, 2004
Signature of:
Title: Director
EpiSource SA

IN WITNESS WHEREOF,



Signature of witness:

this 15th day of December 2004
Date of signing

IN WITNESS WHEREOF,



Signature of witness:

this 15th day of DECEMBER, 2004
Date of signing

Attorney Docket No.: 17811-999

For DFB Pharmaceuticals, Inc.:

Date:

Brooke Smart

Signature of:
Title: *Chief Scientific Officer*
DFB Pharmaceuticals, Inc.

IN WITNESS WHEREOF,

Mark Lewis

Signature of witness:

this 15th day of December 2004
Date of signing

IN WITNESS WHEREOF,

John W. Lewis

Signature of witness:

this 15th day of December 2004
Date of signing

Attorney Docket No.: 17811-999

SCHEDULE A

1. 17811-014-004 (M-14 AU)
Australian Patent Application No. 60098/00
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
2. 17811-014-008 (M-14 CA)
Canadian Patent Application No. 2,379,949
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
3. 17811-014-019 (M-14 EP)
European Patent Application No. 00946228.4
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
4. 17811-014-032 (M-14 JP)
Japanese Patent Application No. 2001-511156
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
5. 17811-014-061 (M-14 WO)
PCT Patent Application No. PCT/IB00/01076
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
6. 17811-014 (M-14)
United States Patent No. 6,548,058
Entitled: "Keratinocyte Culture and Uses Thereof"
7. 17811-014 CIP (M-14 CIP)
United States Patent No. 6,730,513
Entitled: "Keratinocyte Culture and Uses Thereof"

Attorney Docket No.: 17811-999

8. 17811-014 NATL (M-14 NATL)
United States Patent Application No. 10/031,188
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
9. 17811-015 (M-15)
United States Patent No. 5,968,546
Entitled: "Keratinocyte Culture from Precursor Cells"
10. 17811-017 (M-17)
United States Patent No. 6,673,603
Entitled: "Cell Paste Comprising Keratinocytes and Fibroblasts"
11. 17811-017 CIP (M-17 CIP)
United States Patent Application No. 10/324,257
Entitled: "Methods and Compositions for Tissue Regeneration"
12. 17811-017-032 CIP (M-17 CIP JP)
Japanese Patent Application No. 2003-157362
Entitled: "Methods and Compositions for Tissue Regeneration"
13. 17811-017-061 CIP (M-17 CIP WO)
PCT Patent Application No. PCT/US03/27888
Entitled: "Methods and Compositions for Tissue Regeneration"
14. 17811-017-004 (M-17 AU)
Australian Patent Application No. 2001286952
Entitled: "Methods and Compositions for Tissue Regeneration"
15. 17811-017-008 (M-17 CA)
Canadian Patent Application No. 2426107
Entitled: "Methods and Compositions for Tissue Regeneration"

Attorney Docket No.: 17811-999

16. 17811-017-019 (M-17 EP)
European Patent Application No. 01966441.6
Entitled: "Methods and Compositions for Tissue Regeneration"
17. 17811-017-061 (M-17 WO)
PCT Patent Application No. PCT/US01/27104
Entitled: "Methods and Compositions for Tissue Regeneration"
18. 17811-028 (M-28)
United States Patent Application No. 10/655,435
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"
19. 17811-028-061 (M-28 WO)
PCT Patent Application No. PCT/IB03/04506
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"